Fertility preserving treatment of ovarian malignant tumor

doi:10.3760/cma.j.issn.1673-422X.2016.06.021

Abstract

Abstract: As a new type of treatment for ovarian cancer, the fertility sparing surgery is put forward for patients who has fertility requirements and the surgical indication. But the indications and safety are still controversial at present on the international. The operation is based on the traditional surgery way, the retention of the uterus and at least one side of the ovary, and then the corresponding adjuvant chemotherapy and ovarian protection, and choosing the right pregnancy timing based on individual difference, to the excellent oncologic outcomes and the favorable reproductive outcomes.

Key words: Ovarian neoplasms, Fertility, Therapy, Pregnancy

Wei Meng, Yang Yongxiu. Fertility preserving treatment of ovarian malignant tumor[J]. Journal of International Oncology, 2016, 43(6): 475-478.

References

［1］ Kurman RJ, Shih IeM. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory［J］. Am J Surg Pathol, 2010, 34(3): 433-443. DOI: 10.1097/PAS.0b013e3181cf3d79. ［2］ Ditto A, Martinelli F, Bogani G, et al. Longterm safety of fertility sparing surgery in early stage ovarian cancer: comparison to standard radical surgical procedures［J］. Gynecol Oncol, 2015, 138(1): 78-82. DOI: 10.1016/j.ygyno.2015.05.004. ［3］ Kajiyama H. Fertility sparing surgery in patients with early stage epithelial ovarian cancer: implication of survival analysis and lymphadenectomy［J］. J Gynecol Oncol, 2014, 25(4): 270-271. DOI: 10.3802/jgo.2014.25.4.270. ［4］ Billmire DF, Rescorla FJ, Ross JH, et al. Impact of central surgical review in a study of malignant germ cell tumors［J］.J Pediatr Surg, 2015, 50(9): 1502-1505. DOI: 10.1016/j.jpedsurg.2014.12.008. ［5］ González Martín A, Redondo A, Jurado M, et al. GEICO (Spanish group for investigation on ovarian cancer) treatment guidelines in ovarian cancer 2012［J］. Clin Transl Oncol, 2013, 15(7): 509-525. DOI: 10.1007/s12094-012-0995-8. ［6］ Yang ZJ, Liu ZC, Wei RJ, et al. An analysis of prognostic factors in patients with ovarian malignant germ cell tumors who are treated with fertilitypreserving surgery［J］. Gynecol Obstet Invest, 2015, In press. DOI: 10.1159/000381771. ［7］ Park JY, Kim DY, Suh DS, et al. Outcomes of pediatric and adolescent girls with malignant ovarian germ cell tumors［J］. Gynecol Oncol, 2015, 137(3): 418-422. DOI: 10.1016/j.ygyno.2015.03.054. ［8］ Chhabra S, Kutchi I. Fertility preservation in gynecological cancers［J］. Clin Med Insights Reprod Health, 2013, 7: 49-59. DOI: 10.4137/CMRH.S10794. ［9］ Jung KW, Won YJ, Kong HJ, et al. Prediction of cancer incidence and mortality in Korea, 2014［J］. Cancer Res Treat, 2014, 46(2): 124-130. DOI: 10.4143/crt.2014.46.2.124. ［10］ Kajiyama H, Shibata K, Mizuno M, et al. Fertilitysparing surgery in patients with clearcell carcinoma of the ovary: is it possible?［J］. Hum Reprod, 2011, 26(12): 32973302. DOI: 10.1093/humrep/der342. ［11］ Satoh T, Tsuda H, Kanato K, et al. A nonrandomized confirmatory study regarding selection of fertilitysparing surgery for patients with epithelial ovarian cancer: Japan Clinical Oncology Group Study (JCOG1203)［J］. Jpn J Clin Oncol, 2015, 45(6): 595-599. DOI: 10.1093/jjco/hyv032. ［12］ Kajiyama H, Mizuno M, Shibata K, et al. Recurrencepredicting prognostic factors for patients with earlystage epithelial ovarian cancer undergoing fertilitysparing surgery: a multiinstitutional study［J］. Eur J Obstet Gynecol Reprod Biol, 2014, 175(175): 97-102. DOI: 10.1016/j.ejogrb.2014.01.014. ［13］ Leblanc E, Narducci F, Farre I, et al. Radical fimbriectomy: a reasonable temporary riskreducing surgery for selected women with a germ line mutation of BRCA 1 or 2 genes? Rationale and preliminary development［J］. Gynecol Oncol, 2011, 121(3): 472-476. DOI: 10.1016/j.ygyno.2011.02.012. ［14］ Bachmann C, Brucker SY, Kraemer B, et al. The prognostic relevance of node metastases in optimally cytoreduced advanced ovarian cancer［J］. J Cancer Res Clin Oncol, 2015, 141(8): 1475-1480. DOI: 10.1007/s00432-015-1945-y. ［15］ Chatchotikawong U, Ruengkhachorn I, Leelaphatanadit C, et al. 8year analysis of the prevalence of lymph nodes metastasis, oncologic and pregnancy outcomes in apparent earlystage malignant ovarian germ cell tumors［J］. Asian Pac J Cancer Prev, 2015, 16(4): 16091613. ［16］ Kottarathil VD, Antony MA, Nair IR, et al. Recent advances in granulosa cell tumor ovary: a review［J］. Indian J Surg Oncol, 2013, 4(1): 37-47. DOI: 10.1007/s13193-012-0201-z. ［17］ Papic JC, Finnell SM, Slaven JE, et al. Predictors of ovarian malignancy in children: overcoming clinical barriers of ovarian preservation［J］. J Pediatr Surg, 2014, 49(1): 144-147; discussion 147148. DOI: 10.1016/j.jpedsurg.2013.09.068. ［18］ Pereira A, PérezMedina T, Magrina JF, et al. International federation of gynecology and obstetrics staging classification for cancer of the ovary, fallopian tube, and peritoneum: estimation of survival in patients with nodepositive epithelial ovarian cancer［J］. Int J Gynecol Cancer, 2015, 25(1): 49-54. DOI: 10.1097/IGC.0000000000000316. ［19］ Vassilakopoulou M, Boostandoost E, Papaxoinis G, et al. Anticancer treatment and fertility: effect of therapeutic modalities on reproductive system and functions［J］. Crit Rev Oncol Hematol, 2016, 97： 338-334. DOI: 10.1016/j.critrevonc.2015.08.002. ［20］ Chen CA, Lin H, Weng CS, et al. Outcome of 3day bleomycin, etoposide and cisplatin chemotherapeutic regimen for patients with malignant ovarian germ cell tumours: a Taiwanese Gynecologic Oncology Group study［J］. Eur J Cancer, 2014, 50(18): 3161-3167. DOI: 10.1016/j.ejca.2014.10.006. ［21］ Solheim O, Trope CG, Rokkones E, et al. Fertility and gonadal function after adjuvant therapy in women diagnosed with a malignant ovarian germ cell tumor (MOGCT) during the "cisplatin era"［J］. Gynecol Oncol, 2015, 136(2): 224-229. DOI: 10.1016/j.ygyno. 2014.12.010. ［22］ Park CY, Jung SY, Lee KB, et al. The feasibility and efficacy of gonadotropinreleasing hormone agonists for prevention of chemotherapy induced ovarian failure in patient with gynecological malignancies［J］. Obstet Gynecol Sci, 2014, 57(6): 478-483. DOI: 10.5468/ogs.2014.57.6.478. ［23］ Blumenfeld Z. Fertility preservation and GnRHa for chemotherapy: debate［J］. Cancer Manag Res, 2014, 6: 313-315. DOI: 10.2147/CMAR.S66600. ［24］ Gamzatova Z, Komlichenko E, Kostareva A, et al. Autotransplantation of cryopreserved ovarian tissueeffective method of fertility preservation in cancer patients［J］. Gynecol Endocrinol, 2014, 82(2): 141-145. DOI: 10.3109/09513590.2014.945789. ［25］ Fruscio R, Corso S, Ceppi L, et al. Conservative management of earlystage epithelial ovarian cancer: results of a large retrospective series［J］. Ann Oncol, 2013, 24(1): 138-144. DOI: 10.1093/annonc/mds241. ［26］ Karalk A, Tal T, reyen I, et al. Juvenile granulosa cell ovarian tumor: clinicopathological evaluation of ten patients［J］. J Turk Ger Gynecol Assoc, 2015, 16(1): 32-34. DOI: 10.5152/jtgga.2015.15207.

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[4]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[5]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[6]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[7]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua. Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy [J]. Journal of International Oncology, 2024, 51(5): 257-266.
[8]	Wang Peixin, Zhao Jun, Xu Shihong, Jiang Zhaoyang, Wang Xiaoqiang, Yang Hongjuan. Progress of ferroptosis-related mechanisms in osteosarcoma [J]. Journal of International Oncology, 2024, 51(5): 308-311.
[9]	Yang Hao, Shi Guidong, Zhang Chengcheng, Zhang Yue, Zhang Liwen, Fu Maoyong. Comparison of efficacy and safety between sintilimab and tislelizumab in neoadjuvant therapy for advanced esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2024, 51(4): 210-216.
[10]	Sa Qiang, Xu Hangcheng, Wang Jiayu. Advances in immunotherapy for breast cancer [J]. Journal of International Oncology, 2024, 51(4): 227-234.
[11]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong. Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer [J]. Journal of International Oncology, 2024, 51(4): 235-238.
[12]	Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao. Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes [J]. Journal of International Oncology, 2024, 51(3): 143-150.
[13]	Qian Xiaotao, Shi Ziyi, Hu Ge. A real-world clinical study of immunocheckpoint inhibitor maintenance therapy after radical radiotherapy and chemotherapy in stage Ⅲ-ⅣA esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2024, 51(3): 151-156.
[14]	Li Shuyue, Ma Chenying, Zhou Juying, Xu Xiaoting, Qin Songbing. Progress of radiotherapy in oligometastatic non-small cell lung cancer [J]. Journal of International Oncology, 2024, 51(3): 170-174.
[15]	Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan. Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 175-180.